Among the developed VCP inhibitors, ATPase competitive inhibitors, CB-5083 and CB-5339, have reached clinical trials (https://clinicaltrials.gov trial number NCT02243917 & NCT04372641) by demonstrating effective anti-tumor activity across various tumor models [31, 69, 70]. This evidence concerns the gene DNAH8 and neoplasm.